The 1,3,4-oxadiazole ring is a five-membered heterocycle comprising one oxygen and two nitrogen atoms, widely investigated in medicinal chemistry for its aromatic stability and bioisosterism with the carbonyl group in amides and esters. Heterocyclic scaffolds make up more than 85 percent of FDA-approved drug molecules, owing to their ability to form various intermolecular interactions including hydrogen bonding, metal coordination, π–π stacking, hydrophobic interactions, and van der Waals contacts. Several biological activities have been reported for 1,3,4-oxadiazoles, including antimicrobial, anti-inflammatory, antioxidant, and anticancer effects, with reported anticancer mechanisms including inhibition of growth factor receptors such as EGFR and VEGFR and induction of apoptosis in several tumor types. However, oxadiazole-based compounds had not previously been explored specifically for oligodendroglioma.

The synthesis proceeded through acid-catalyzed condensation of the appropriate hydrazides with aromatic aldehydes in absolute ethanol under reflux to afford hydrazone intermediates, which were then oxidatively cyclized using iodine and potassium carbonate in dimethyl sulfoxide at 100 °C for three to six hours to yield the final oxadiazole derivatives. Seven compounds were produced, designated A1 through A3 and B1 through B4, with the A series bearing a 5-chloro-2-nitrophenyl substituent and the B series bearing a 4-cyanophenyl substituent at the C-5 position of the oxadiazole ring. Characterization was carried out by FT-IR, proton NMR, carbon-13 NMR, and electron ionization mass spectrometry, with the infrared spectra supporting complete ring closure by the disappearance of the N–H stretching band and the amide carbonyl C=O stretching band of the hydrazones, alongside the appearance of characteristic C=N stretching of the oxadiazole ring and C–O–C asymmetric stretching.

Biological evaluation used the MTT colorimetric assay, which is based on the reduction of a yellow tetrazolium salt by mitochondrial dehydrogenase enzymes in metabolically active cells, producing an insoluble purple formazan product whose absorbance correlates directly with cell viability. Cells were plated at 10,000 cells per well in 96-well microplates, incubated for 24 hours, and exposed to serial concentrations of the test compounds ranging from 10 to 1,000 µg/mL, with cisplatin run in parallel as a reference drug. The IC50 values of all seven compounds were lower than that of cisplatin, which recorded an IC50 of 212.27 µg/mL against HS683 cells. Compounds bearing the 4-cyanophenyl group at C-5 were consistently more active than their A analogs, with IC50 values approximately half those of the matched pairs.

The selectivity index, calculated as the ratio of the IC50 against normal human astrocytes to the IC50 against HS683 cells, showed a clear advantage of the synthesized compounds over cisplatin, whose SI of 1.25 indicates near-equal toxicity toward tumor and normal cells. All seven compounds gave SI values greater than 1, with B2 achieving the highest SI of 14.55, followed by A2 with an SI exceeding 12.15, whose IC50 against normal human astrocytes exceeded 1,000 µg/mL, indicating minimal toxicity toward healthy brain cells. This favorable selectivity profile is particularly significant given that treatment-related adverse effects remain difficult to manage with current oligodendroglioma therapies, which typically involve radiotherapy and chemotherapy with temozolomide or the PCV regimen in conjunction with surgical resection.

Structure–activity relationship analysis revealed that the thiophen-2-yl group at the C-2 position produced the lowest IC50 values in both series, lower than those of their phenyl-substituted counterparts. Within compounds B, the activity order was B2 with the thienyl substituent, followed by B1 with pyridin-4-yl, B4 with 4-methylphenyl, and B3 with 4-fluorophenyl. Notably, pyridin-4-yl was the least active substituent among compounds A but the second-most active among compounds B, indicating that its contribution to activity depends on the electronic and steric character of the C-5 substituent. The thienyl compounds also possessed the highest selectivity indices in both series, suggesting that the thiophen-2-yl group was beneficial not only for cytotoxic potency but also for selectivity toward HS683 cells over normal astrocytes.

Molecular docking studies were performed against three kinase targets selected for their relevance to glioma pathogenesis: phosphatidylinositol 3-kinase alpha, cyclin-dependent kinase 2, and focal adhesion kinase. PI3Kα was included because of its role in the PI3K/AKT/mTOR pathway, CDK2 was included because of its overexpression in low-grade glioma subtypes, and FAK was selected based on its overexpression in glioma. The docking protocol was validated by re-docking the co-crystallized ligands, with root-mean-square deviation values all below 2.0 Å, confirming that the computational approach reliably reproduced experimental binding modes. Against PI3Kα, compounds B1 and B2 formed the strongest predicted interactions in the study, both forming hydrogen-acceptor contacts with LYS890 at distances of approximately 2.95 Å, with per-contact interaction energies of −9.0 and −8.8 kcal/mol respectively, involving the nitrile nitrogen of the 4-cyanophenyl group.

Against CDK2, compounds A produced scores of −6.654 to −7.087 kcal/mol, while compounds B ranged from −5.914 to −6.101 kcal/mol. B1 formed the richest interaction network among compounds B, with six contacts including two hydrogen-donor/acceptor interactions with LEU83 and PHE82, two hydrogen-acceptor contacts with LYS129 and ASN132, and a π–H contact with ILE10. B2 achieved a hydrogen-donor interaction between its sulfur atom and ASP145, suggesting that the sulfur atom of the thiophen-2-yl group is directly involved in the interaction. Against FAK, A2 achieved the strongest score among the synthesized compounds, and in both A2 and B2 the oxadiazole ring nitrogens served as the primary interaction atoms, forming two hydrogen-acceptor contacts with CYS502. This sulfur-specific contact with ASP145 was not observed for the phenyl- or heteroaryl-substituted analogs, providing a computational rationale for the superior activity of the thienyl compounds.

All seven compounds satisfied Lipinski’s rule of five, with molecular weights ranging from 248.24 to 319.68 g/mol and cLogP values ranging from 2.13 to 3.25, indicating moderate lipophilicity suitable for membrane permeation. The synthesized compounds had no hydrogen-bond donors and four to six hydrogen-bond acceptors, all below the maximum recommended limit. Topological polar surface area values ranged from 62.71 to 112.98 Ų, with compounds A showing higher values than compounds B. All final compounds were predicted to have high gastrointestinal absorption, and none were predicted to act as P-glycoprotein substrates, which may indicate a lower likelihood of efflux-mediated resistance. Notably, B1, B3, and B4 were predicted to permeate the blood–brain barrier, a relevant physicochemical feature for compounds intended to target glioma, although these predictions reflect theoretical permeability rather than confirmed central nervous system distribution and would require experimental validation.

The authors acknowledge that the proposed kinase targets are based on molecular docking and require experimental confirmation, and that further evaluation across additional glioma cell lines and in vivo models would help establish the broader therapeutic relevance of B2. Within the context of prior research, thioacetamide-based 1,3,4-oxadiazole derivatives have shown activity against C6 rat glioma cells, while ferulic acid- and caffeic acid-based oxadiazole hybrid derivatives have demonstrated activity against human glioblastoma cell lines U87, T98G, and LN229. Oxadiazole-based Akt/FAK inhibitors have also shown cytotoxic effects against C6 cells, supporting the relevance of FAK as a target within this chemical class. B2 extends this body of evidence to a previously unexamined glioma cell line and substituent pattern, reinforcing its potential as a lead candidate for future anti-glioma development.

Subject of Research: 1,3,4-Oxadiazole derivatives as potential anti-glioma agents: synthesis, characterization, in vitro cytotoxic activity against HS683 cells, and molecular docking

Article Title: 1,3,4-Oxadiazole derivatives as potential anti-glioma agents: synthesis, characterization, in vitro cytotoxic activity against HS683 cells, and molecular docking

Article References: Hashim, R. J., Alsaad, H. N., & Salman, H. H. (2026). 1,3,4-Oxadiazole derivatives as potential anti-glioma agents: synthesis, characterization, in vitro cytotoxic activity against HS683 cells, and molecular docking. Pharmacia, 73, Article e198079. https://doi.org/10.3897/pharmacia.73.e198079

Image Credits: AI Generated

DOI: 10.3897/pharmacia.73.e198079

Keywords: 1,3,4-oxadiazole, anti-glioma agents, HS683, oligodendroglioma, molecular docking, MTT assay, selectivity index, drug-likeness, medicinal chemistry, kinase inhibitors, Oxadiazole, derivatives

The 1,3,4-oxadiazole is a compact five-membered ring containing two nitrogen atoms and one oxygen atom, and it has long been a favourite building block in medicinal chemistry because it appears in compounds with antibacterial, antifungal, anti-inflammatory and anticancer activity. The researchers, led by Rekha Singh and Jagadish Singh of Guru Ghasidas Vishwavidyalaya in Bilaspur, together with Balaji Wamanrao Matore and colleagues, drew on two decades of their own prior work with this scaffold. Their design strategy placed a phenyl ring directly on the oxadiazole core, a motif also found in the approved drug zibotentan, and attached a second chlorinated phenyl ring through an imine, or CH=N, linker at the five-position of the ring.

Synthesis proceeded in three straightforward steps. Substituted aldehydes were first condensed with semicarbazide hydrochloride in ethanol to form Schiff base intermediates, which were then cyclised with iodine and potassium carbonate in 1,4-dioxane at 80 degrees Celsius to build the oxadiazole ring. A final condensation with different chloro-substituted aldehydes delivered the nine target compounds, R1 through R9, in yields above 90 percent. Every product was confirmed by FT-IR, proton NMR and mass spectrometry, with the diagnostic imine proton appearing between 8.73 and 8.99 parts per million in the NMR spectra, and melting points recorded for each purified solid.

Before any wet-lab testing, the team ran a battery of computational experiments. Density functional theory calculations using the DMol3 code suggested that all nine compounds are more chemically reactive than the kinase inhibitor sorafenib, with R3, R4 and R6 showing the smallest HOMO-LUMO gaps at 0.086 Hartree, a measure that correlates with a molecule’s willingness to engage in electronic interactions. Target prediction servers, including PASS and SwissTargetPrediction, then pointed the researchers toward kinase receptors, a family of enzymes heavily implicated in breast cancer biology through receptors such as VEGFR2, EGFR, PDGFR and HER2.

VEGFR2, the vascular endothelial growth factor receptor 2, emerged as the priority target because of its central role in angiogenesis, the process by which tumours recruit new blood vessels to fuel their growth and spread. Blocking VEGFR2 is a clinically validated strategy in breast cancer management, and the researchers selected the crystal structure 4ASD from the Protein Data Bank for docking studies. After validating their protocol by re-docking the co-crystallised ligand and achieving root-mean-square deviations well below the accepted two angstrom threshold, they docked all nine compounds into the ATP binding pocket using three independent algorithms: CDOCKER, LibDock and AutoDock Vina.

The docking results told a remarkably consistent story. Compound R3 achieved the highest CDOCKER interaction energy at 41.54 and the best LibDock score at 130.38, and it formed fifteen separate contacts with the protein, including hydrogen bonds to GLU885, ASP1046 and LYS868, three residues known to stabilise ATP-competitive inhibitors at the hinge region of the kinase. Twelve additional hydrophobic contacts with residues such as LEU840, VAL848, PHE918 and CYS1045 locked the molecule deep in the pocket. Fourteen of these interactions were shared with the co-crystallised reference ligand, meaning R3 essentially mimics the binding mode of a proven VEGFR2 inhibitor. Binding free energy calculations confirmed the picture, with R3 showing the most favourable stability of the series at minus 84.42 kilocalories per mole, compared with minus 142.01 for sorafenib.

Structure-activity relationship analysis revealed the decisive role of chlorine positioning. Derivatives bearing meta and para chloro substituents on their phenyl rings, compounds R1 through R4, consistently outperformed those with ortho substitution, compounds R5 through R9. The explanation is steric: an ortho chlorine crowds the space near the imine linker and prevents the molecule from adopting the flat, extended conformation needed to slot into the VEGFR2 pocket. The ortho-substituted compounds formed almost no favourable interactions in docking, showed weaker binding free energies, and translated this deficit directly into higher IC50 values in the cell assays. It is a textbook example of how a single atom, moved a few angstroms, can flip a molecule from active to inert.

The computational predictions were then put to the test in the laboratory. Using the MTT assay against MCF-7 breast cancer cells at concentrations ranging from 5 to 80 micromolar, all nine compounds showed moderate to potent, concentration-dependent cytotoxicity, with IC50 values spanning 8.068 to 17.343 micromolar. Three compounds, R1, R3 and R4, fell below the 10 micromolar threshold, and R3 led the series at 8.068 micromolar, close to the 4.051 micromolar recorded for doxorubicin under the same conditions. Microscopy of treated cultures showed reduced cell density and altered morphology relative to untreated controls, consistent with the viability data.

Pharmacokinetic modelling added a further layer of optimism. SwissADME predictions indicated high gastrointestinal absorption and good oral bioavailability for the whole series, with moderate lipophilicity, LogP values of 3.3 to 3.5, and a low topological polar surface area of 51.28 square angstroms, a balance well suited to membrane permeability. The ProTox-II server classified all compounds in toxicity class 4 with an LD50 of 375 milligrams per kilogram and predicted them to be non-carcinogenic, non-mutagenic and non-immunotoxic, although moderate hepatotoxicity was flagged for the series, mirroring the profile of sorafenib itself. The authors note two caveats for future optimisation: moderate aqueous solubility may complicate formulation, and the predicted ability to cross the blood-brain barrier raises the possibility of off-target central nervous system exposure that must be managed in an anticancer context.

The study’s authors are careful to frame the work as an early-stage screening effort. MCF-7 served as the initial model, and broader evaluation across additional cancer cell lines and normal cell models will be needed to establish selectivity and safety, particularly for R3, which the team identifies as the lead candidate for further development. Even so, the internal consistency of the data is compelling: the same substitution pattern that produced the best docking scores also produced the strongest binding free energies and the lowest IC50 values, and the key residues engaged by R3 match those exploited by clinically approved VEGFR2 inhibitors such as sorafenib. For a scaffold as chemically accessible as the 1,3,4-oxadiazole, synthesised in three steps from cheap starting materials with yields above 90 percent, that combination of potency, predictability and synthetic simplicity makes R3 a lead worth watching as VEGFR2-targeted breast cancer drug discovery moves forward.

Subject of Research: Design and evaluation of 1,3,4-oxadiazole derivatives as VEGFR2-targeted anticancer agents against breast cancer

Article Title: Design, synthesis, SAR, in silico and in vitro evaluation of 1, 3, 4-oxadiazole derivatives against breast cancer

Article References: Singh, R., Matore, B. W., Murmu, A., Lakra, N., Banjare, P., Namdeo, K. P., Roy, P. P., & Singh, J. (2026). Design, synthesis, SAR, in silico and in vitro evaluation of 1, 3, 4-oxadiazole derivatives against breast cancer. Discover Chemistry, 3(1), Article 539. https://doi.org/10.1007/s44371-026-00898-w

Image Credits: AI Generated

DOI: 10.1007/s44371-026-00898-w

Keywords: breast cancer, 1,3,4-oxadiazole, VEGFR2, MCF-7, molecular docking, structure-activity relationship, ADMET, drug discovery, angiogenesis, kinase inhibitors, MTT assay, medicinal chemistry

The rationale behind the work rests on a strategy that chemists call molecular hybridization. Rather than screening random libraries or chasing a single protein target, the researchers deliberately stitched together two pharmacologically privileged fragments, each with an impressive track record of its own. The pyrimidine ring, a six-membered aromatic system containing two nitrogen atoms, is a core component of the nucleobases that make up DNA and RNA, and it appears in numerous FDA-approved medicines. Perhaps the most famous modern example is osimertinib, a tyrosine kinase inhibitor used to treat lung cancer, in which the pyrimidine moiety is an essential part of the molecular framework that engages its biological target.

The second fragment, the 1,3,4-oxadiazole, is a five-membered ring containing two nitrogen atoms and one oxygen atom. Its azole functional group, characterized by alternating carbon-nitrogen double bonds, acts as a hydrogen-bond acceptor and can form strong interactions with the binding pockets of proteins. This ring has been incorporated into agents with antidepressant, antiviral, anti-inflammatory, antitubercular, antimitotic, and anticancer activities. AstraZeneca researchers developed zibotentan, a molecule containing the 1,3,4-oxadiazole unit, as an anticancer drug candidate for prostate cancer, illustrating the ring’s clinical relevance. By combining these two motifs through a flexible phenoxy linker, the team hoped to create a structurally complementary scaffold whose biological activity would exceed the sum of its parts.

The synthetic route begins with an inexpensive and familiar starting material: 2-hydroxybenzoic acid, better known as salicylic acid. The researchers first esterified the acid with methanol under sulfuric acid catalysis, a twelve-hour reflux that delivered methyl 2-hydroxybenzoate in 92 percent yield. Treatment of this ester with hydrazine hydrate converted it into 2-hydroxybenzohydrazide, a hydrazide bearing a free phenolic hydroxyl group that would prove crucial in later steps. Each intermediate was rigorously characterized using proton and carbon-13 nuclear magnetic resonance spectroscopy, mass spectrometry, and melting point analysis, with high-resolution mass measurements matching calculated values to within a few thousandths of a mass unit.

The pivotal ring-forming step came next. The hydrazide was coupled with pyrimidine-5-carboxylic acid using HATU, a powerful peptide-coupling reagent, together with triethylamine in dry tetrahydrofuran. Adding Burgess reagent, a mild dehydrating agent, then cyclodehydrated the resulting diacylhydrazide intermediate to close the 1,3,4-oxadiazole ring, furnishing the key phenolic oxadiazole building block in 60 percent yield. This intermediate was subsequently reacted with 2,4-dichloropyrimidine in the presence of the base DIPEA, which selectively displaced one of the two chlorine atoms through the phenolic oxygen, producing a chloropyrimidine ether in 79 percent yield. The remaining chlorine atom served as a chemical handle for the final diversification step.

That final step is where the library took shape. The chloropyrimidine intermediate was heated under reflux with ten different aryl amines, each catalyzed by a small amount of p-toluenesulfonic acid, generating ten target compounds designated 11a through 11j. The aryl amines spanned a deliberate range of electronic characters: electron-donating methoxy groups in single, double, and triple arrangements; simple methyl substituents; a dimethylamino group; and electron-withdrawing chloro, bromo, nitro, and dinitro groups. Yields for the final coupling ranged from 68 to 83 percent, and the products, mostly crystalline white solids with melting points approaching or exceeding 280 degrees Celsius, were purified by column chromatography and confirmed by the full battery of analytical techniques.

With the library in hand, the team turned to biological testing using the MTT assay, a colorimetric method in which living cells convert a yellow tetrazolium dye into purple formazan crystals, allowing cell viability to be quantified by light absorption at 570 nanometers. Four human cancer cell lines were challenged with the compounds: MCF-7 breast cancer cells, A549 lung cancer cells, Colo-205 colon cancer cells, and A2780 ovarian cancer cells. Etoposide, a topoisomerase inhibitor widely used in chemotherapy, served as the positive control, and a range of concentrations from 0.5 to 2 micromolar was tested over 24-hour incubations. Critically, the compounds were also tested against Vero cells, a normal kidney epithelial cell line from the African green monkey, to gauge whether the cytotoxicity was selective for cancer cells.

The results were striking. Compound 11a, bearing a 3,4,5-trimethoxyphenyl group, emerged as the star of the series, with half-maximal inhibitory concentrations of 0.13 micromolar against MCF-7 breast cancer cells, 0.27 micromolar against A549 lung cancer cells, 0.32 micromolar against Colo-205 colon cancer cells, and 0.17 micromolar against A2780 ovarian cancer cells. Against breast and ovarian cancer cells, this single compound was roughly an order of magnitude more potent than etoposide, which registered 2.19 and 1.38 micromolar respectively in those lines. Compounds 11b through 11f, spanning the dimethoxy, monomethoxy, methyl, and dimethylamino variants, also beat the positive control in most cell lines, with IC50 values ranging from roughly 0.4 to 3.3 micromolar. The electron-poor compounds 11g through 11j, carrying halogen and nitro substituents, were consistently the weakest performers, with activities in the 3.7 to 4.6 micromolar range and, in some cases, no detectable activity against particular cell lines.

Just as important as the potency was the selectivity. Every one of the ten compounds showed markedly weaker toxicity toward normal Vero cells, with IC50 values all exceeding 28 micromolar, and some exceeding 38 micromolar. That means the best compound was more than two hundred times more toxic to breast cancer cells than to normal kidney cells, a therapeutic window that, if it holds up in more advanced models, would be highly desirable for an anticancer agent. The structure-activity relationship that emerged from the data is clear and chemically intuitive: electron-donating methoxy groups favor activity, and the more methoxy groups, the better, with the 3,4,5-trimethoxy pattern of 11a standing at the top of the hierarchy. Swapping methoxy for methyl groups diminished potency, and electron-withdrawing substituents eroded it further, suggesting that the electronic richness of the aryl amine fragment plays a decisive role in whatever interaction these molecules make inside cancer cells.

The trimethoxyphenyl motif itself carries an intriguing pedigree, appearing in other biologically active natural products and synthetic agents, and its prominence here hints at a possible binding interaction worth pursuing. The authors are careful to frame this as preliminary work: the compounds were tested in vitro, no molecular target has yet been identified, and the mechanism by which these hybrids kill cancer cells remains to be established. The next steps for such a program typically involve expanding the cell panel, probing the compounds’ effects on cell cycle and apoptosis, identifying the protein targets through affinity-based methods, and evaluating pharmacokinetic properties. Still, the study demonstrates the power of rational fragment fusion in medicinal chemistry. By welding a pyrimidine ring, the scaffold of a blockbuster lung cancer drug, to a 1,3,4-oxadiazole, the ring at the heart of a prostate cancer candidate, and tuning the aryl amine cap with methoxy groups, the researchers have produced a lead compound whose nanomolar potency and favorable selectivity profile make it a genuinely promising starting point for further anticancer drug development.

Subject of Research: Synthesis and anticancer evaluation of aryl-substituted pyrimidine–1,3,4-oxadiazole hybrid compounds

Article Title: Synthesis and biological evaluation of aryl-substituted pyrimidine–1,3,4-oxadiazole derivatives as potential anticancer agents

Article References: Mukkavilli, P., Konidena, L. N. S., Valluru, K. R., Somaiah, N., & Subbarao, M. (2026). Synthesis and biological evaluation of aryl-substituted pyrimidine–1,3,4-oxadiazole derivatives as potential anticancer agents. Results in Chemistry, 31, Article 103865. https://doi.org/10.1016/j.rechem.2026.103865

Image Credits: AI Generated

DOI: 10.1016/j.rechem.2026.103865

Keywords: pyrimidine, 1,3,4-oxadiazole, anticancer agents, molecular hybridization, MTT assay, MCF-7, A549, structure-activity relationship, medicinal chemistry, heterocyclic compounds, etoposide, drug discovery

Pseudomonas aeruginosa is an opportunistic Gram-negative bacterium that thrives in the damaged tissue of severe burns, where the loss of the skin barrier and prolonged hospitalization create ideal conditions for colonization. The organism is intrinsically resistant to many antimicrobial classes and readily acquires further resistance, and its capacity to form biofilms—structured bacterial communities encased in a self-produced extracellular matrix—makes eradication exceptionally difficult. Biofilms shield cells from antibiotics and immune defenses, driving therapeutic failure and recurrence in burn units and intensive care settings worldwide.

To gauge the scale of the problem in their region, the team collected 75 non-duplicate clinical P. aeruginosa isolates from patients at educational hospitals in Hamedan, Iran, between October 2024 and March 2025. Forty-nine isolates came from burn wounds and 26 from respiratory samples. Using Kirby-Bauer disk diffusion testing interpreted against Clinical and Laboratory Standards Institute breakpoints, the researchers found resistance was highest for ceftazidime at 78.67 percent, imipenem at 72 percent, and gentamicin at 69.33 percent. Overall, 57 isolates, or 76 percent, met the internationally accepted definition of multidrug resistance, meaning non-susceptibility to at least one agent in three or more antimicrobial categories.

Biofilm formation proved nearly universal. Seventy-four of the 75 isolates, or 98.7 percent, produced biofilms in the crystal violet microtiter assay, and every multidrug-resistant isolate did so, with 37 of the 57 classified as strong producers. From the burn-wound collection, the investigators selected nine isolates for detailed analysis—seven multidrug-resistant and two non-multidrug-resistant—all of which showed strong or intermediate biofilm formation, alongside the reference strain PAO1 as a standardized comparator.

The compound under investigation, (5-(3-methoxyphenyl)-1,3,4-oxadiazol-2-yl)(pyridin-2-yl)methanol, is a heterocyclic scaffold bearing a 3-methoxyphenyl substituent and a pyridin-2-yl methanol moiety, synthesized and characterized previously with purity above 95 percent confirmed by NMR. Against the nine selected burn isolates, the derivative yielded geometric mean minimum inhibitory and bactericidal concentrations of 20.54 and 41.21 micrograms per milliliter for planktonic cells. For biofilm-associated cells, the minimum biofilm inhibitory and eradication concentrations were 52.56 and 105.11 micrograms per milliliter, respectively. The higher eradication value reflects the well-known tolerance of mature biofilms, whose extracellular matrix limits drug penetration and access to embedded cells.

Checkerboard microdilution assays then tested whether the oxadiazole could potentiate gentamicin, an aminoglycoside protein synthesis inhibitor, and imipenem, a broad-spectrum carbapenem. Against planktonic cells, the gentamicin combination produced geometric mean fractional inhibitory and bactericidal concentration indices of 0.54 and 0.50, while the imipenem combination yielded 0.72 and 0.62. Against biofilm cells, the corresponding fractional biofilm indices ranged from 0.55 to 0.62, indicating similar gains in antibiofilm activity. Full synergy, defined as an index below 0.5, was observed in three of the nine isolates, with most others showing partial synergy, and no antagonism was detected in any combination.

The most mechanistically revealing results came from gene expression analysis. When the researchers exposed PAO1 and two clinical isolates to sub-inhibitory concentrations of the oxadiazole, quantitative real-time PCR revealed significant, concentration-dependent downregulation of two biofilm-associated genes: lasR, the master transcriptional regulator of the quorum-sensing system that coordinates virulence factor production and biofilm maturation, and algD, which encodes GDP-mannose dehydrogenase, the key enzyme in alginate biosynthesis that determines biofilm matrix thickness and stability. Log2 fold changes reached as low as minus 4.12 for both genes, with regression analysis showing strong concentration-response relationships and coefficients of determination between 0.888 and 0.969.

Because these transcriptional changes occurred at concentrations below the biofilm-inhibitory endpoint, the authors interpret them as evidence that the compound interferes with the regulatory machinery of biofilm formation rather than simply killing cells. They caution, however, that reduced gene expression alone does not establish a definitive molecular mechanism, since changes in viability or broader transcriptional responses could contribute, and that exopolysaccharide production and quorum-sensing signal levels were not directly measured in this study. Plausible mechanisms proposed for oxadiazoles elsewhere include disruption of bacterial membrane integrity, inhibition of essential enzymatic pathways, interference with nucleic acid synthesis, and altered permeability that enhances antibiotic uptake.

The dose-reduction implications are clinically significant. In previous work by the same group, the compound showed no significant cytotoxicity at concentrations up to 15.62 micrograms per milliliter, with an estimated IC50 range of 15.62 to 31.25 micrograms per milliliter. Combining the oxadiazole with gentamicin or imipenem lowered the fractional concentrations needed for antibacterial and antibiofilm effects, potentially allowing the compound to operate within its non-cytotoxic range while restoring activity to antibiotics against which the isolates had substantial resistance. The authors emphasize that the findings support the derivative as a promising adjunctive or alternative strategy for biofilm-related multidrug-resistant P. aeruginosa infections in burn patients, but that translation requires pharmacokinetic profiling, stable formulations, direct cytotoxicity testing of the combinations, and rigorous in vivo efficacy and toxicity studies in animal burn-infection models before clinical use can be considered.

Subject of Research: Antibacterial and antibiofilm activity of a 1,3,4-oxadiazole derivative against multidrug-resistant Pseudomonas aeruginosa from burn wound infections

Article Title: Antibacterial and antibiofilm properties of 1,3,4-oxadiazoles against multidrug-resistant Pseudomonas aeruginosa isolated from burn infections – an in vitro study

Article References: Nazari, M., Majzoobi, M. M., Alikhani, M. Y., & Imani Fooladi, A. A. (2026). Antibacterial and antibiofilm properties of 1,3,4-oxadiazoles against multidrug-resistant Pseudomonas aeruginosa isolated from burn infections – an in vitro study. International Microbiology. https://doi.org/10.1007/s10123-026-00890-5

Image Credits: AI Generated

DOI: 10.1007/s10123-026-00890-5

Keywords: Pseudomonas aeruginosa, burn wound infection, multidrug resistance, biofilm, 1,3,4-oxadiazole, lasR, algD, quorum sensing, synergistic therapy, gentamicin, imipenem, antimicrobial resistance